Detectable end of radiation prostate specific antigen assists in identifying men with unfavorable intermediate ‐risk prostate cancer at high risk of distant recurrence and cancer‐specific mortality
ConclusionsEOR‐PSA can assist in predicting DMFS and PCSS among UIR patients, suggesting a clinically meaningful time point for considering intensification of treatment in clinical trials of intermediate‐risk men. (Source: The Prostate)
Source: The Prostate - March 9, 2018 Category: Urology & Nephrology Authors: Jonathan Hayman, Ryan Phillips, Di Chen, Jamie Perin, Amol K. Narang, Janson Trieu, Noura Radwan, Stephen Greco, Curtiland Deville, Todd McNutt, Daniel Y. Song, Theodore L. DeWeese, Phuoc T. Tran Tags: ORIGINAL ARTICLE Source Type: research
Reduced vitamin D receptor (VDR) expression and plasma vitamin D levels are associated with aging ‐related prostate lesions
ConclusionsOur data indicate that the aging prostate suffers from an imbalance on the intricate mechanism of tissue regulation by the vitamin D responsive system. We argue that the status of VDR expression might be determinant for the development of histopathological alterations in the aging prostate, which include premalignant lesions. (Source: The Prostate)
Source: The Prostate - March 6, 2018 Category: Urology & Nephrology Authors: Gabriel H. Campolina ‐Silva, Bruna T. Maria, Germán A.B. Mahecha, Cleida A. Oliveira Tags: ORIGINAL ARTICLE Source Type: research
Reduced vitamin D receptor (VDR) expression and plasma vitamin D levels are associated with aging ‐related prostate lesions
The Prostate, EarlyView. (Source: The Prostate)
Source: The Prostate - March 5, 2018 Category: Urology & Nephrology Source Type: research
AR ‐V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration‐resistant prostate cancer patients
The Prostate, EarlyView. (Source: The Prostate)
Source: The Prostate - March 5, 2018 Category: Urology & Nephrology Source Type: research
---
The Prostate, Ahead of Print. (Source: The Prostate)
Source: The Prostate - March 5, 2018 Category: Urology & Nephrology Source Type: research
AR ‐V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration‐resistant prostate cancer patients
ConclusionThe CTC clusters and AR‐V7‐positive CTC clusters detected were important for assessing the response to abiraterone or enzalutamide therapy and for predicting disease outcome. (Source: The Prostate)
Source: The Prostate - March 5, 2018 Category: Urology & Nephrology Authors: Takatsugu Okegawa, Naoki Ninomiya, Kazuki Masuda, Yu Nakamura, Mitsuhiro Tambo, Kikuo Nutahara Tags: ORIGINAL ARTICLE Source Type: research
Does docetaxel prolong survival of patients with non ‐metastatic castration‐resistant prostate cancer?
ConclusionsEarlier induction of docetaxel in nmCRPC patients may prolong OS. Further prospective studies in more patients will be required to confirm our findings. (Source: The Prostate)
Source: The Prostate - February 23, 2018 Category: Urology & Nephrology Authors: Kagenori Ito, Takahiro Kimura, Hajime Onuma, Ryuji Tabata, Tatsuya Shimomura, Kenta Miki, Masayuki Tomita, Shin Egawa Tags: ORIGINAL ARTICLE Source Type: research
Does docetaxel prolong survival of patients with non ‐metastatic castration‐resistant prostate cancer?
The Prostate, EarlyView. (Source: The Prostate)
Source: The Prostate - February 23, 2018 Category: Urology & Nephrology Source Type: research
The androgen receptor malignancy shift in prostate cancer
The Prostate, EarlyView. (Source: The Prostate)
Source: The Prostate - February 23, 2018 Category: Urology & Nephrology Source Type: research
---
The Prostate, Ahead of Print. (Source: The Prostate)
Source: The Prostate - February 23, 2018 Category: Urology & Nephrology Source Type: research
The androgen receptor malignancy shift in prostate cancer
ConclusionsReinterpretation of prostate cancer genomic classification systems in light of the AR malignancy shift may improve our ability to predict clinical outcomes and treat patients appropriately. Identifying and targeting the molecular factors that contribute to the AR malignancy shift is not trivial but by doing so, we may be able to develop new strategies for the treatment or prevention of prostate cancer. (Source: The Prostate)
Source: The Prostate - February 23, 2018 Category: Urology & Nephrology Authors: Ben T. Copeland, Sumanta K. Pal, Eric C. Bolton, Jeremy O. Jones Tags: REVIEW ARTICLE Source Type: research
Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion
ConclusionMore extensive PLND at RP provides improved staging information and consequently is associated with lower CSM in D'Amico intermediate‐ and high‐risk PCa patients without evidence of LNI. Hence, more extensive PLND should be recommended in such individuals. (Source: The Prostate)
Source: The Prostate - February 20, 2018 Category: Urology & Nephrology Authors: Felix Preisser, Marco Bandini, Michele Marchioni, Sebastiano Nazzani, Zhe Tian, Raisa S. Pompe, Nicola Fossati, Alberto Briganti, Fred Saad, Shahrokh F. Shariat, Hans Heinzer, Hartwig Huland, Markus Graefen, Derya Tilki, Pierre I. Karakiewicz Tags: ORIGINAL ARTICLE Source Type: research
Issue Information
(Source: The Prostate)
Source: The Prostate - February 20, 2018 Category: Urology & Nephrology Tags: ISSUE INFORMATION Source Type: research
